TrovaGene Inc. Confirms It Has Regained Its Rights to Transrenal Technology for Non-Invasive Prenatal Testing and Cancer

August 2011
Biomedical Market Newsletter;8/12/2011, Vol. 21, p352
The article reports that TrovaGene Inc. has regained its rights to transrenal technology for non-invasive prenatal applications and cancer by terminating its license agreement with Sequenom Inc. Thomas Adams, TrovaGene's chairman, says that the recovery gives them the opportunity to expand their business in women's healthcare market. Moreover, the generated data by TrovaGene of the next-generation genomic representation of fetal transrenal sequences in urine from pregnant women is discussed.


Related Articles

  • Deals roundup.  // Medical Device Daily;9/23/2008, Vol. 12 Issue 203, p3 

    The article reports on the exclusive rights secured by Sequenom involving fundamental patent rights for digital polymerase chain reaction (PCR) technologies and methods under a licensing agreement with Genomic Nanosystems. The licensed rights include U.S. Patent Numbers 6,143,496 and 6,291,559...

  • Deals roundup.  // Medical Device Daily;10/31/2008, Vol. 12 Issue 213, p3 

    The article reports on the exclusive licensing agreement between Xenomics and Sequenom. Under the agreement, the latter will be given exclusive rights to use the patents of the former for the development of prenatal research and diagnostic products. Xenomics also has patents in other fields of...

  • Trovagene grants Duke license for AML testing.  // Medical Device Daily;12/28/2012, Vol. 16 Issue 250, p7 

    The article reports on the non-exclusive license agreements signed by Trovagene with Duke University and Duke University Health Systems for its nucleophosmin protein.

  • Do women understand prenatal screening for fetal abnormality? Ockleford, Elizabeth; Berryman, Julia; Hsu, Ron // British Journal of Midwifery;Jul2003, Vol. 11 Issue 7, p445 

    Examines pregnant women's understanding of the purpose of prenatal screening for fetal abnormality in Great Britain. Ultrasound scans; Serum testing; Decision-making.

  • Overutilization of antenatal care in Norway. Backe, Bjorn // Scandinavian Journal of Public Health;Jun2001, Vol. 29 Issue 2 

    :Background: It has long been a common belief in Norway that all pregnant women attend antenatal care, but no documentation has been provided. In 1984, official guidelines were issued recommending a reduction of the number of routine visits. However, no studies have been performed in order to...

  • NUVELO ASSIGNS PATENTS TO SEQUENOM.  // Biotech Business;Nov2003, Vol. 16 Issue 11, p4 

    Reports on the patent assignment and license agreement signed by Nuvelo Inc. and SEQUENOM Inc. as of November 2003.

  • TrovaGene stops Sequenom, regains transrenal tech rights.  // Medical Device Daily;8/11/2011, Vol. 15 Issue 150, p3 

    The article reports on the termination of a license agreement between TrovaGene and Sequenom in 2011.

  • Your pregnancy: New tests, new fears. Rothman, Barbara Katz // Glamour;Sep93, Vol. 91 Issue 9, p272 

    Discusses the ethical issues and psychological consequences of prenatal diagnosis. Option given to women; Effect of knowing too much in advance; Lack of a guarantee for a healthy baby; Forms of prenatal diagnosis; Failures of prenatal counseling.

  • why are women saying no to amnio? Lombardi, Lisa // Redbook;Jan2003, Vol. 200 Issue 1, p94 

    Investigates the reasons for the ambivalence of pregnant women toward amniocentesis. Information on why women do not feel compelled to find out if there is a problem on their pregnancy; Tests which are being hated by pregnant women; Theories behind the decision of a couple to skip amniocentesis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics